Most Popular Stocks - AMEX/NASDAQ/NYSE
Upgrades and Downgrades
Market Snapshot
- After-Hours Report: Weekly Wrap
- After-Hours Report: OZK -20%, LLNW -11.4%, TEAM -5%, SKX +8%, PYPL +7%, ISRG +2%, AXP +0.5% following earnings/guidance:
- After-Hours Report: AA +3.3%, URI -4.3% following earnings/guidance:
- After-Hours Report: NFLX +11.7%, UAL +5.1%, LRCX +4.0%, CREE -4.1%, IBM -3.8% following earnings/guidance:
- After-Hours Report: JELD -11%, ADBE +6%, JBHT +1% following earnings/guidance
Timely updates of equity ratings changes issued by brokerage firms.
Updated: 5 hours 23 min ago
NFLX: B. Riley FBR reits Buy
B. Riley FBR issues rating change for NFLX
DPZ: Maxim Group ups to Buy
Maxim Group issues rating change for DPZ
IDTI: Craig Hallum cuts to Hold
Craig Hallum issues rating change for IDTI
NFLX: Pivotal Research Group reits Buy
Pivotal Research Group issues rating change for NFLX
LLEX: Williams Capital Group cuts to Hold
Williams Capital Group issues rating change for LLEX
FTCH: Deutsche Bank starts at Buy
Deutsche Bank issues rating change for FTCH
IFF: Deutsche Bank ups to Buy
Deutsche Bank issues rating change for IFF
ZBH: Barclays starts at Underweight
Barclays issues rating change for ZBH
TFX: Barclays starts at Equal Weight
Barclays issues rating change for TFX
SYK: Barclays starts at Overweight
Barclays issues rating change for SYK
MDT: Barclays starts at Overweight
Barclays issues rating change for MDT
HRC: Barclays starts at Equal Weight
Barclays issues rating change for HRC
EW: Barclays starts at Underweight
Barclays issues rating change for EW
CNMD: Barclays starts at Equal Weight
Barclays issues rating change for CNMD
BSX: Barclays starts at Overweight
Barclays issues rating change for BSX
BDX: Barclays starts at Equal Weight
Barclays issues rating change for BDX
BAX: Barclays starts at Underweight
Barclays issues rating change for BAX
AVNS: Barclays starts at Equal Weight
Barclays issues rating change for AVNS
ABT: Barclays starts at Overweight
Barclays issues rating change for ABT
VFC: Wedbush starts at Neutral
Wedbush issues rating change for VFC
Pages
Stocks Up on Unusual Volume
Stocks Down on Unusual Volume
Upgrades and Downgrades
- STN: Scotia Howard Weil ups to Sector Outperform
- GPS: Standpoint Research ups to Buy
- NFLX: BMO Capital Markets reits Outperform
- PYPL: BMO Capital Markets reits Outperform
- AXP: BMO Capital Markets reits Market Perform
- HOG: BMO Capital Markets cuts to Market Perform
- VRNS: Wedbush starts at Neutral
- DOCU: Wedbush starts at Neutral
- ADBE: Wedbush starts at Neutral
- CLDR: Wedbush starts at Neutral
- PANW: Wedbush starts at Neutral
- CTXS: Wedbush starts at Neutral
- NUAN: Wedbush starts at Outperform
- NICE: Wedbush starts at Outperform
- TENB: Wedbush starts at Outperform
- ZS: Robert W. Baird resumes at Outperform
- CIG: UBS cuts to Neutral
- CHKP: Robert W. Baird resumes at Neutral
- CHU: UBS cuts to Neutral
- CHA: UBS cuts to Neutral
IPO News
- Caliburn International files for a $100 million IPO
- US IPO Week Ahead: Yeti coolers and a billion-dollar payments company lead 5-IPO week
- Respiratory device provider Vapotherm files for a $58 million IPO
- US IPO Weekly Recap: IPOs are put through the ringer with 7 completed deals
- Non-opioid pain therapy developer Centrexion Therapeutics files for a $86 million IPO
- Chinese financing platform Pintec Technology sets terms for $41 million US IPO
- Experience management software provider Qualtrics International files for a $200 million IPO
- SolarWinds prices IPO at $15, the low end of the revised range
- Niu Technologies prices downsized IPO at $9, the low end of the revised range
- It's only logical: Gene editing biotech LogicBio Therapeutics prices $70 million IPO below the range at $10
- BankFlorida files and sets terms for a $65 million IPO
- Chinese e-scooter maker Niu Technologies decreases proposed US IPO deal size
- Antibody biotech Tiziana Life Sciences decreases proposed US IPO deal size
- SolarWinds downsizes IPO and decreases range; deal size cut by half
- Extended release drug maker Osmotica Pharmaceuticals prices half-sized IPO at $7
- PhaseBio Pharmaceuticals prices IPO at $5, below the range
- Jackpot: Studio City International prices US IPO at $12.50 high end
- Extended release drug maker Osmotica Pharmaceuticals decreases proposed IPO deal size
- Israel-based Phase 3 biotech Gamida Cell sets terms for $50 million IPO
- IT services provider Valtech postpones $100 million IPO